Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC359408PMC
http://dx.doi.org/10.1503/cmaj.1031734DOI Listing

Publication Analysis

Top Keywords

mild sars
4
sars elderly
4
elderly patients
4
mild
1
elderly
1
patients
1

Similar Publications

Background: Post-COVID19 syndrome is characterized by signs and symptoms that occur within 3 months of the onset of COVID19 acute phase and last at least 2 months. In the past 3 years, cognitive impairment has frequently been associated with COVID19 with descriptions of attentional, executive, memory, and language disorders. Many studies have assessed these cognitive disturbances using online and telephone tests, often in isolated interviews on a cross-sectional design in high-income countries.

View Article and Find Full Text PDF
Article Synopsis
  • The COVID-19 pandemic influenced population-level immune responses through infections, lockdowns, and vaccination efforts, potentially impacting various immune-mediated diseases.
  • In a study of 1,895 asymptomatic individuals living with HIV, researchers assessed how these factors modified inflammatory profiles and immune responses between October 2019 and October 2021.
  • Results showed that while mild COVID-19 infections had minimal long-term immune effects, lockdowns significantly increased immune responsiveness, and vaccinations moderately reduced it, suggesting lockdowns may have unexpected immunological consequences that warrant further investigation.
View Article and Find Full Text PDF

Characteristics of patients with non-severe infections of different SARS-CoV-2 omicron subvariants in China.

Front Med (Lausanne)

December 2024

Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Shijiazhuang, Hebei, China.

Objective: The aim of this study was to explore the clinical characteristics of patients infected with different Omicron subvariants presenting non-severe disease, evaluate the safety and efficacy of Azvudine for treatment of COVID-19, in order to broaden understanding of Omicron subvariant infections.

Method: A total of 244 individuals with Omicron subvariant (BA.2.

View Article and Find Full Text PDF

In vitro to clinical efficacy: Neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 strains.

J Infect Chemother

December 2024

Department of Infectious Diseases, Hiroshima University Hospital, 1-2-3 Kasumi, Minamiku, Hiroshima 734-8551, Japan. Electronic address:

Introduction: Neutralizing antibodies have been approved for coronavirus disease 2019 (COVID-19) treatment; however, no study has clarified the link among their neutralizing effect in vitro, the period of infectious virus shedding, and symptoms in the acute phase. Here, we aimed to assess the duration of virus shed and fever in patients with mild COVID-19 stratified by their characteristics and type of neutralizing antibody administered.

Methods: We evaluated the efficacy of neutralizing antibodies in terms of the duration of infectious virus excretion and fever in three groups: patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta strain treated with REGEN-CoV2 (REGN-CoV2 group) and patients infected with Omicron strain treated with S309 (S309 group) or untreated (untreated group).

View Article and Find Full Text PDF

Introduction: Upon infection, T cell-driven B cell responses in GC reactions induce memory B cells and antibody-secreting cells that secrete protective antibodies. How formation of specifically long-lived plasma cells is regulated via the interplay between specific B and CD4+ T cells is not well understood. Generally, antibody levels decline over time after clearance of the primary infection.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!